B. Riley Securities resumed coverage on LifeMD with a new price target
$LFMD
Medical/Nursing Services
Health Care
B. Riley Securities resumed coverage of LifeMD with a rating of Buy and set a new price target of $16.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/10/2024 | $12.00 | Buy | Lake Street |
| 12/4/2024 | $7.00 | Neutral | Mizuho |
| 8/23/2024 | $11.00 | Buy | B. Riley Securities |
| 6/5/2024 | $12.00 | Overweight | KeyBanc Capital Markets |
| 11/30/2023 | $10.00 | Buy | Craig Hallum |
| 7/21/2023 | $7.00 | Overweight | Cantor Fitzgerald |
| 7/3/2023 | $9.00 | Buy | H.C. Wainwright |
| 3/10/2022 | $14.00 | Buy | Colliers Securities |
Lake Street initiated coverage of LifeMD with a rating of Buy and set a new price target of $12.00
Mizuho initiated coverage of LifeMD with a rating of Neutral and set a new price target of $7.00
B. Riley Securities resumed coverage of LifeMD with a rating of Buy and set a new price target of $11.00
NEW YORK, Dec. 24, 2024 (GLOBE NEWSWIRE) -- LifeMD, Inc. (NASDAQ:LFMD), a leading provider of virtual primary care services, today announced that its Board of Directors has authorized a cash dividend to holders of the Company's 8.875% Series A Cumulative Perpetual Preferred Stock (NASDAQ:LFMDP) equal to $0.5546875 per share. The preferred dividend will be paid on January 15, 2025, to holders of record at the close of business on January 3, 2025. About LifeMD, Inc. LifeMD® is a leading provider of virtual primary care. LifeMD offers telemedicine, access to laboratory and pharmacy services, and specialized treatment across more than 200 conditions, including primary care, men's and women'
While 8 out of 10 U.S. adults trying to lose weight are eager to reach their goal as soon as possible, they agree that weight loss is an ongoing process requiring consistent attention and effort* Medifast (NYSE:MED), the health and wellness company known for its habit-based and coach-guided lifestyle solution OPTAVIA®, today shared findings from a recent independent survey. Commissioned by Medifast and conducted by the third-party market research firm Talker Research, the goal of the survey was to better understand American perceptions of weight loss medications and their role in health journeys, while also identifying areas where further support is necessary. The survey of 2,000 nation
NEW YORK, Dec. 05, 2024 (GLOBE NEWSWIRE) -- LifeMD, Inc. (NASDAQ:LFMD), a leading provider of virtual primary care services, announces that management will be participating in the Mizuho Health Care Conference: Medical Device, Services, Technology and Distribution, taking place December 11, 2024 at the Sofitel New York. Management will hold one-on-one meetings with investors throughout the day. Institutional investors interested in attending the conference and meeting with LifeMD management should contact their Mizuho Securities representative. About LifeMD, Inc.LifeMD® is a leading provider of virtual primary care. LifeMD offers telemedicine, access to laboratory and pharmacy se
4 - LifeMD, Inc. (0000948320) (Issuer)
4 - LifeMD, Inc. (0000948320) (Issuer)
4 - LifeMD, Inc. (0000948320) (Issuer)
S-8 - LifeMD, Inc. (0000948320) (Filer)
8-K - LifeMD, Inc. (0000948320) (Filer)
8-K - LifeMD, Inc. (0000948320) (Filer)
SC 13G/A - LifeMD, Inc. (0000948320) (Subject)
SC 13G/A - LifeMD, Inc. (0000948320) (Subject)
SC 13G - LifeMD, Inc. (0000948320) (Subject)
NEW YORK, Dec. 24, 2024 (GLOBE NEWSWIRE) -- LifeMD, Inc. (NASDAQ:LFMD), a leading provider of virtual primary care services, today announced that its Board of Directors has authorized a cash dividend to holders of the Company's 8.875% Series A Cumulative Perpetual Preferred Stock (NASDAQ:LFMDP) equal to $0.5546875 per share. The preferred dividend will be paid on January 15, 2025, to holders of record at the close of business on January 3, 2025. About LifeMD, Inc. LifeMD® is a leading provider of virtual primary care. LifeMD offers telemedicine, access to laboratory and pharmacy services, and specialized treatment across more than 200 conditions, including primary care, men's and women'
Medifast (NYSE:MED), the health and wellness company known for its habit-based and coach-guided lifestyle solution, OPTAVIA®, today reported results for the third quarter ended September 30, 2024. Third Quarter 2024 Revenue of $140.2 million, with revenue per active earning coach of $4,672 Independent active earning OPTAVIA coaches of 30,000 Net income of $1.1 million (non-GAAP adjusted net income of $3.9 million) Income per diluted share of $0.10 (non-GAAP adjusted earnings per share ("EPS") of $0.35) Cash, Cash Equivalents, and Investment Securities of $170.0 million with no debt "Medical innovation has transformed the weight loss industry, so at Medifast we're creating a hea
NEW YORK, Oct. 24, 2024 (GLOBE NEWSWIRE) -- LifeMD, Inc. (NASDAQ:LFMD), a leading provider of virtual primary care services, announces that it will report financial results for the three and nine months ended September 30, 2024 after the close of the U.S. financial markets on November 7, 2024 and will host a conference call beginning at 4:30 p.m. Eastern time. Conference Call & Webcast Details Date:Thursday, November 7thTime:4:30 p.m. Eastern timeToll-Free Dial-In:800-717-1738International Dial-In:646-307-1865Conference ID:73461Live & Archived Webcast:Link About LifeMD, Inc.LifeMD is a leading provider of virtual primary care. LifeMD offers telemedicine, access to laboratory and pharmac
NEW YORK, May 29, 2024 (GLOBE NEWSWIRE) -- LifeMD, Inc. (NASDAQ:LFMD), a leading provider of virtual primary care services, is set to join the broad-market Russell 3000® Index at the conclusion of the 2024 Russell U.S. Indexes annual reconstitution, effective at the open of U.S. equity markets on Monday, July 1st, according to a preliminary list of additions posted Friday, May 24th. The annual Russell U.S. Indexes reconstitution captures the 4,000 largest U.S. stocks as of Tuesday, April 30th, ranking them by total market capitalization. Membership in the U.S. all-cap Russell 3000® Index, which remains in place for one year, means automatic inclusion in the large-cap Russell 1000® Ind
NEW YORK, April 29, 2024 (GLOBE NEWSWIRE) -- LifeMD, Inc. (NASDAQ:LFMD), a leading provider of virtual primary care services, today announced the appointment of Calum MacRae, M.D., Ph.D., a clinician, researcher and educator at Harvard Medical School, as an independent member of its Board of Directors. "We are delighted to welcome Dr. MacRae to the LifeMD Board of Directors. He brings deep experience in cardiology, internal medicine and clinical innovation, with a focus on disease management and the implementation of novel solutions to improve the delivery of virtual healthcare services," said Justin Schreiber, Chairman and Chief Executive Officer of LifeMD. "Aside from being a world-reno
NEW YORK, June 20, 2023 (GLOBE NEWSWIRE) -- LifeMD, Inc. (NASDAQ:LFMD), a leading provider of virtual primary care services, today announced the appointment of William (Will) J. Febbo, Chief Executive Officer and Director of OptimizeRx Corporation (NASDAQ:OPRX) to its Board of Directors. OptimizeRx is a leading provider of digital point-of-care technology solutions that help patients start and stay on therapy. "We are extremely pleased to welcome Will to our Board. He brings to LifeMD a depth of experience in building and managing healthcare companies, and pioneering technology to improve the experience for healthcare providers and patients," said Justin Schreiber, Chairman and Chief Exec